Synopsis: A healthcare services company that most investors have never heard of quietly turned ₹1 lakh into ₹3.3 crore over five years, while building a business that tripled its profits in just one financial year.
A Healthcare company has spent over three decades in relative obscurity, but its recent financial performance is making it hard to ignore. The Mumbai-based company, formerly known as Overseas Synthetics Limited, provides life sciences and healthcare solutions across the globe, with expertise in mass screening, diagnostics, and healthcare sciences used by hospitals and institutions worldwide. Its FY26 results tell a story of explosive growth that few small-cap healthcare names can match right now.
Since January 2021, levels of ₹2 per share, One Global Service has emerged as a massive wealth creator. The stock currently trades around ₹665, representing a staggering 33,150% gain. An investment of ₹1 lakh would have grown to about ₹3.3 crore in just five years. At its all-time high of ₹790, the same investment would have been worth nearly ₹3.95 crore.
A Business That Has Found Its Footing
Incorporated in 1992, One Global Service Provider spent years operating under a different identity before pivoting to healthcare services. Today, the company operates under the brand 1Global and serves clients across life sciences and diagnostics – sectors that have seen sustained demand following the global focus on healthcare infrastructure. The business model centres on providing end-to-end healthcare solutions, giving it exposure to both institutional clients and the broader diagnostics ecosystem. What changed in FY26 is not just the scale of revenues – it is the pace at which the company converted that scale into profit.
Numbers That Demand Attention
One Global Service Provider’s revenue from operations jumped from ₹4 crore in FY21 to ₹498 crore in FY26 – a rise of over 12,000% in just five years. This is not incremental growth. Operating profit followed the same trajectory, climbing from ₹2 crore in FY21 to ₹93 crore in FY26, with operating margins expanding to 19% – a sign that the company is not just growing revenues but doing so with improving efficiency. Net profit tells the same story, rising from ₹2 crore in FY21 to ₹70 crore in FY26, a 3,400% surge.
Also, revenue from operations nearly tripled from ₹147 crore in FY25 to ₹498 crore in FY26, reflecting a sharp acceleration in order execution and client reach. Operating profit surged from ₹25 crore to ₹93 crore over the same period, with margins expanding from 17% to 19%. Net profit followed suit, jumping from ₹18 crore in FY25 to ₹70 crore in FY26 – a near four-fold rise in a single financial year.
A Balance Sheet Built on Earnings, Not Debt
While many fast-growing small-cap companies fund their expansion through borrowings, One Global Service Provider has taken the opposite route. Long-term borrowings stood at just ₹0.03 crore as of March 2026 – effectively making it a debt-free company. Total equity expanded from ₹71.72 crore to ₹141.23 crore, driven entirely by retained profits as reserves and surplus grew from ₹52.18 crore to ₹121.69 crore.
Trade receivables did rise sharply – from ₹57.65 crore to ₹216.58 crore – a figure worth watching as the company scales. However, the absence of debt and a clean auditor opinion with no modifications suggest the fundamentals remain sound.
Rewarding Shareholders Along the Way
The board has recommended a final dividend of ₹1 per share for FY26 – a 10% payout on the face value of ₹10. While modest in absolute terms, the gesture signals management’s confidence in the company’s cash generation and its intent to share gains with long-term shareholders.
The stock’s 33,150% return over five years has already rewarded those who spotted this story early. The question now is whether the underlying business can sustain the kind of growth that justifies continued investor interest – and the FY26 numbers suggest the answer, at least for now, is yes.
Incorporated in 1992 and formerly known as Overseas Synthetics Limited, One Global Service Provider Limited is a Mumbai-based healthcare services company operating under the brand 1Global. The company provides life sciences and healthcare solutions globally, with expertise in mass screening, diagnostics, and healthcare sciences serving hospitals and institutions. It is listed on BSE under scrip code 514330.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post ₹2 to ₹665: Healthcare Stock Turns ₹1 Lakh Into ₹3.3 Cr in Just 5 Yrs appeared first on Trade Brains.
Original Article
(Disclaimer – This post is auto-fetched from publicly available RSS feeds. Original source: Tradebrains. All rights belong to the respective publisher.)
